Document is current
Any future updates will be listed below
-
Authors
de Tute, Ruth M.
Cook, Gordon https://orcid.org/0000-0003-1717-0412
Cairns, David A. https://orcid.org/0000-0002-2338-0179
Brown, Julia M.
Cavenagh, Jamie
Ashcroft, A. John
Snowden, John A. https://orcid.org/0000-0001-6819-3476
Yong, Kwee
Tholouli, Eleni
Jenner, Matthew
Hockaday, Anna
Drayson, Mark T.
Morris, Treen C. M.
Rawstron, Andy C.
Owen, Roger G.
-
Funding
Funding for this research was provided by:
Cancer Research UK (CRUK/06/018], CRUK/06/018, CRUK/06/018, CRUK/06/018, CRUK/06/018)
- License Information
-
More Information
Article History
Received: 1 August 2023
Revised: 12 October 2023
Accepted: 27 November 2023
First Online: 9 January 2024
Competing interests
: GC has received grant/research support from Celgene/BMS, Janssen, and Takeda & Honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Takeda, Roche, Oncopeptides and Sanofi. DAC has received research funding top institution from Celgene Corporation, Amgen, Millennium Pharmaceuticals, and Merck Sharp and Dohme. JMB is Deputy Chair of the NIHR HTA Funding Committee. AJA has received speaking/advisory boards fees from Janssen, Celgene and Amgen. JAS declares honoraria for speaking from Janssen and Gilead, an advisory board from Medac, and IDMC membership for a clinical trial supported by Kiadis. ET has received advisory board &/or speakers fees from Celgene, Gilead/Kite, Janssen, Jazz, Novartis and Pfizer. Also received consultancy for educational materials from Gilead/Kite MTD has shares in Abingdon Health (a biodiagnostics company). ACR AbbVie: Advisory Board, Research Funding &/or Honoraria from AbbVie, Beckman Coulter, Celgene, Gilead, Janssen and Pharmacyclics, Consultancy fees from Gilead and Pharmacyclics, Royalties, research funding and honararia from BD Bio-sciences and is director of Medical Education and Developments Services Ltd. RGO has received honoraria from Celgene, Janssen, Astra Zeneca, Beigene and advisory boards fees from Janssen and Beigene.
